Non-Small-Cell Lung Cancer
Conditions
Interventions
Both URLC10 and CDCA1 peptides restricted to HLA-A*2402 (0.5mg for each) are administered four times once a week.
Both URLC10 and CDCA1 peptides restricted to HLA-A*2402 (1.0mg for each) are administe
Sponsors
Department of Respiratory Medicine, Juntendo University School of Medicine
Human Genome Center, Institute of Medical Science, University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically and/or cytologically proven NSCLC, which is refractory to any chemotherapy. 2.ECOG performance status 0-2 3.No severe postoperative complications 4.Age between 20 to 80 5.3000/mm3<WBC<15000/mm3 Hemoglobin>8.0g/dl Platelet count>75000/mm3 Asparate transaminase < 150IU/L Alanine transaminase < 150IU/L Total bilirubin < 3.0mg/dl PaO2 > 60 torr Serum creatinine < 2.0mg/dl 6.Life expectancy > 3 months 7.HLA-A*2402 8.Able and willing to give valid written informed consent
Exclusion criteria
Exclusion criteria: 1.Pregnancy 2.Breastfeeding 3.Concurrent treatment with steroids or immunosuppressing agent 4.No other malignancy requiring treatment 5.No curative traumatic wound 6.Decision of unsuitableness by principal investigator or physician-in-charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of safety and adverse effects of vaccination therapy and determination of the recommended dose for phase II trial | — |
Countries
Japan
Outcome results
None listed